White Paper
Exploring Immunotherapies: Beyond Checkpoint Inhibitors
Immunotherapy is an emerging class of cancer treatment, which stimulates the body’s immune system to fight cancer. With the approval of three checkpoint inhibitors (ipilimumab, pembrolizumab and nivolumab) by the FDA in the past five years, immunotherapies are seen as exciting treatments able to elicit durable cures. Download our white paper to discover: Emerging immunotherapeutic […]
Jun 1, 2016
White Paper
Non-invasive Quantification of Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatisis (NASH) are emerging as the most prevalent causes of liver disease in Western countries. There are various methods used to evaluate fat content as well as other characteristics of the liver. Medical imaging provides a non-invasive approach to quantify tissue characteristics of the liver while reducing errors in […]
Sep 1, 2015
White Paper
Immunotherapy – Concept Turned Reality
While using the body’s own immune system as a therapeutic approach to fight cancer is not a new concept in oncology, recent successes in clinical studies are making immunotherapy a reality, as it exploits the antitumor capabilities of resident immune cells within the body. This white paper provides an overview of the immune system and […]
Jul 20, 2015
White Paper
Blood Pressure Evaluation During Early Phase Trials
As we know, more attention is being paid to blood pressure (BP) effects in new chemical entities under development for non-hypertension indications, especially when these are not anticipated or thoroughly defined during drug development. Discovering negative results for BP elevation in early trials, would allow more informed planning for BP safety monitoring in later trials. Download […]
Nov 3, 2014
White Paper
ECHO Inter/Intra-Reader Variability
BioTelemetry Research performed a blinded reading to define the variability between inter-reader and intra-reader assessments. The reading was conducted for 58 ECHO studies by two physicians and 29 ECHOs re-read by the same reader. Download our white paper to discover the findings between inter-reader and intra-reader variability for several ECHO Cardiogram parameters, including: Protocol information ECHO […]
Sep 4, 2014
White Paper
The assessment of drug-induced changes in the QT and QTc interval has become a necessary component of drug development. This is because of the potential for new drugs with suspected or known effects on the heart to cause life-threatening delayed cardiac repolarization. A study was conducted to evaluate the effects of low and high therapeutic […]
Aug 3, 2014
GENERAL INQUIRIES:
Toll-Free: 1.877.267.3324
Local: 1.301.214.7600
Fax: 1.301.214.7601
BTRinfo@gobio.com
BUSINESS DEVELOPMENT:
Local: 1.301.214.7628
BTRbusiness@gobio.com
CLINICAL TRIALS SUPPORT:
Toll Free: 1.877.324.8326
BTRsupport@gobio.com
MID-ATLANTIC:
One Preserve Parkway
Suite 600
Rockville, MD 20852
USA
NORTHEAST:
155 Corporate Woods
Suite 180
Rochester, NY 14623
USA
WEST COAST:
400 Oyster Point Blvd
Suite 339
South San Francisco, CA 94080
USA
EUROPE:
Building 3 Chiswick Park
Suite 258
566 Chiswick High Road
London, W4 5YA
UK
Connect with Us for the latest on our clinical trials services, including medical imaging and cardiac safety testing
Phone: 888.312.BEAT (2328)
Fax: 610.828.8048
Contact: Heather Getz, EVP, CFO & CAO
Phone: 800.908.7103
InvestorRelations@biotelinc.com
Phone: 800.908.7103